Lördag 28 December | 02:26:45 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-10-24 08:00 Kvartalsrapport 2025-Q3
2025-07-11 08:00 Kvartalsrapport 2025-Q2
2025-05-22 N/A Årsstämma
2025-04-17 08:00 Kvartalsrapport 2025-Q1
2025-02-07 08:00 Bokslutskommuniké 2024
2024-11-08 - Kvartalsrapport 2024-Q3
2024-09-23 - Extra Bolagsstämma 2024
2024-07-05 - Kvartalsrapport 2024-Q2
2024-05-17 - X-dag ordinarie utdelning NICA 0.00 SEK
2024-05-16 - Årsstämma
2024-04-26 - Kvartalsrapport 2024-Q1
2024-02-09 - Bokslutskommuniké 2023
2023-10-27 - Kvartalsrapport 2023-Q3
2023-07-07 - Kvartalsrapport 2023-Q2
2023-05-05 - X-dag ordinarie utdelning NICA 0.00 SEK
2023-05-04 - Årsstämma
2023-04-28 - Kvartalsrapport 2023-Q1
2023-02-10 - Bokslutskommuniké 2022
2022-11-11 - Kvartalsrapport 2022-Q3
2022-09-15 - Extra Bolagsstämma 2022
2022-08-19 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning NICA 0.00 SEK
2022-06-02 - Årsstämma
2022-04-29 - Kvartalsrapport 2022-Q1
2022-02-08 - Bokslutskommuniké 2021
2021-10-29 - Kvartalsrapport 2021-Q3
2021-08-27 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag ordinarie utdelning NICA 0.00 SEK
2021-05-27 - Årsstämma
2021-05-07 - Kvartalsrapport 2021-Q1
2021-02-26 - Bokslutskommuniké 2020
2020-10-30 - Kvartalsrapport 2020-Q3
2020-08-21 - Kvartalsrapport 2020-Q2
2020-05-29 - X-dag ordinarie utdelning NICA 0.00 SEK
2020-05-28 - Årsstämma
2020-02-26 - Extra Bolagsstämma 2020
2020-02-24 - Kvartalsrapport 2020-Q1
2020-02-07 - Bokslutskommuniké 2019
2019-10-25 - Kvartalsrapport 2019-Q3
2019-08-27 - Kvartalsrapport 2019-Q2
2019-05-31 - X-dag ordinarie utdelning NICA 0.00 SEK
2019-05-29 - Årsstämma
2019-05-10 - Kvartalsrapport 2019-Q1
2019-02-15 - Bokslutskommuniké 2018
2018-11-23 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-06-01 - X-dag ordinarie utdelning NICA 0.00 SEK
2018-05-31 - Årsstämma
2018-04-25 - Kvartalsrapport 2018-Q1
2018-02-23 - Bokslutskommuniké 2017
2017-11-23 - Kvartalsrapport 2017-Q3
2017-08-25 - Kvartalsrapport 2017-Q2
2017-06-02 - X-dag ordinarie utdelning NICA 0.00 SEK
2017-06-01 - Årsstämma
2017-05-19 - Kvartalsrapport 2017-Q1
2017-02-23 - Bokslutskommuniké 2016
2016-11-17 - Kvartalsrapport 2016-Q3
2016-09-12 - Extra Bolagsstämma 2016
2016-08-26 - Kvartalsrapport 2016-Q2
2016-06-01 - X-dag ordinarie utdelning NICA 0.00 SEK
2016-05-31 - Årsstämma
2016-05-20 - Kvartalsrapport 2016-Q1
2016-02-19 - Bokslutskommuniké 2015
2015-11-26 - Kvartalsrapport 2015-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Nanologica är ett life science tools-bolag som utvecklar, tillverkar och säljer avancerade insatsvaror till läkemedelsproducerande företag. Nanologicas silikabaserade produkter är speciellt framtagna för rening av peptidläkemedel, såsom insulin och GLP-1-analoger. Nanologica verkar på en global nischmarknad för läkemedel för behandling av diabetes och obesitas. Nanologica grundades 2004 och har sitt huvudkontor i Södertälje.
2024-02-22 12:25:00

Today, Nanologica AB (publ) held an extraordinary general meeting, whereby the following resolutions were adopted.

For more detailed information on the content of the resolutions, please see the complete notice of the extraordinary general meeting that is available on the company’s website, www.nanologica.com.
 
Resolution regarding approval of the board of directors’ resolution to issue shares with preferential rights for existing shareholders
The general meeting resolved to approve the board of directors’ resolution on an issue of new shares with pre-emptive rights for existing shareholders which was resolved by the board of directors on 30 January 2024, subject to subject to approval by the general meeting.
 
The rights issue comprises an issue of not more than 8,032,476 shares which entails an increase of the company’s share capital with not more than SEK 3,293,538.358523. The new shares are issued at a subscription price of SEK 6.75 per share. The right to subscribe for new shares shall belong to those who on the record date for the new issue are registered as shareholders in the company. The record date for participation in the new issue is 26 February 2024. One (1) existing share entitles to one (1) subscription right, and nine (9) subscriptions rights entitle to subscription of two (2) new shares.
 
Resolution on reduction of the share capital
The extraordinary general meeting also resolved to reduce the company's share capital by not more than SEK 3,293,538.358523 for allocation to non-restricted equity. The share capital shall be reduced by an amount in SEK corresponding to the amount with which the share capital increases through the rights issue. The reduction shall be made without cancellation of shares.
 
Resolution on authorization for the board of directors
The extraordinary general meeting further resolved to authorize the board of directors for the period up to the next annual meeting of shareholders to resolve, whether on one or several occasions, to issue not more than 1,481,481 shares, corresponding to an increase of the share capital of not more than SEK 607,448.38 (calculated without regard to the resolution on reduction of the share capital referred to above). The board of directors shall be authorised to adopt decisions on an issue of shares with deviation from the shareholders’ pre-emption rights and/or an issue in kind or an issue by way of set-off or otherwise on such terms and conditions as referred to in the Swedish Companies Act.
 
The new shares shall be issued at a subscription price of SEK 6.75 per share, corresponding to the subscription price in the rights issue. The share premium shall be transferred to the unrestricted premium reserve. The reason to propose that the board of directors shall be authorised to resolve on an issue with deviation from the shareholders’ pre-emption rights is that the board of directors shall be able to accommodate a potential oversubscription in the rights issue and take advantage of the opportunity to provide the company with additional capital in a time and cost-effective manner and/or expand the shareholder base with one or more shareholders of strategic importance to the company.